On Friday, Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) released topline results from the Phase 3 trial of the combined mRNA vaccine candidate against influenza and COVID-19 in healthy individuals 18-64 years of age. The combination candidate comprises Pfizer’s mRNA-based influenza vaccine candidate with the companies’ licensed COVID-19 vaccine. The Phase 3 trial measured two primary immunogenicity objectives (immunogenicity against SARS-CoV-2 and immunogenicity against influenza A and B), of which one was met. Also Read: Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows. Compared to a licensed influenza vaccine, the trivalent (tIRV) formulation demonstrated influenza A responses, including a continued trend of higher influenza A responses versus a licensed influenza vaccine, while it showed lower geometric mean titers ...